Are you Dr. Yu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 39 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
50 N Medical Dr
Salt Lake City, UT 84132Phone+1 801-581-2121- Is this information wrong?
Summary
- Dr. Margaret Yu, MD is an oncologist in Salt Lake City, Utah. She is currently licensed to practice medicine in Utah and California.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2000 - 2003- University of Utah HealthResidency, Internal Medicine, 1997 - 2000
Medical College of WisconsinClass of 1997
Certifications & Licensure
CA State Medical License 2016 - 2025
UT State Medical License 1998 - 2018
Publications & Presentations
PubMed
- 20 citationsAssociation of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.Felix Y. Feng, Shibu Thomas, Fred Saad, Michael Gormley, Margaret K. Yu, Deborah Ricci, Brendan Rooney, Sabine Brookman-May, Sharon Anne McCarthy, David Olmos, Simon C...> ;JAMA Oncology. 2021 Jul 1
- 6 citationsBlood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as Th...Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stéphane Oudard, Felix Y. Feng, Yashoda Rajpurohit, Karen Urtishak, Deborah Ricci, Brend...> ;Clinical Cancer Research. 2021 Jun 10
- 2 citationsImpact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.Arpit Rao, Howard I. Scher, Peter De Porre, Margaret K. Yu, Anil Londhe, Keqin Qi, Michael J. Morris, Charles J. Ryan> ;ESMO Open. 2020 Nov 1
- Join now to see all
Press Mentions
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (Apalutamide)December 19th, 2019
Erleada Cuts Risk of Death by 25% in Localized Castration-Resistant Prostate Cancer, Phase 3 Trial FindsOctober 2nd, 2019
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (Apalutamide)September 27th, 2019- Join now to see all
